Cargando…
New Insights in the Treatment of SAPHO Syndrome and Medication Recommendations
Synovitis, acne, pustulosis, hyperostosis, osteitis (SAPHO) syndrome is a rare autoinflammatory disease characterized by dermatological disorders and osteoarticular inflammatory lesions. This article reviews the application of biologics and other treatments based on the therapeutic target and the si...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9013916/ https://www.ncbi.nlm.nih.gov/pubmed/35444448 http://dx.doi.org/10.2147/JIR.S353539 |
_version_ | 1784688101980897280 |
---|---|
author | Cheng, Wei Li, Fen Tian, Jing Xie, Xi Chen, Jin-Wei Peng, Xiao-Fei Tang, Qi Ge, Yan |
author_facet | Cheng, Wei Li, Fen Tian, Jing Xie, Xi Chen, Jin-Wei Peng, Xiao-Fei Tang, Qi Ge, Yan |
author_sort | Cheng, Wei |
collection | PubMed |
description | Synovitis, acne, pustulosis, hyperostosis, osteitis (SAPHO) syndrome is a rare autoinflammatory disease characterized by dermatological disorders and osteoarticular inflammatory lesions. This article reviews the application of biologics and other treatments based on the therapeutic target and the size of molecules in SAPHO syndrome. We found that drugs, especially biologics, have different effects on bone, joint, and skin damage. This may relate to the different inflammatory pathways involved in the osteoarticular and cutaneous symptoms in SAPHO patients. In this study, we provide stratified medication recommendations for SAPHO syndrome. Patients with osteoarticular symptoms can consider tumor necrosis factor blockers, JAK inhibitor, interleukin (IL)-1 inhibitor, and IL-17 inhibitor. Patients with cutaneous symptoms should consider IL-17 and JAK inhibitors. Apremilast, Tripterygium wilfordii Hook F, and bisphosphonates are other effective treatments. |
format | Online Article Text |
id | pubmed-9013916 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-90139162022-04-19 New Insights in the Treatment of SAPHO Syndrome and Medication Recommendations Cheng, Wei Li, Fen Tian, Jing Xie, Xi Chen, Jin-Wei Peng, Xiao-Fei Tang, Qi Ge, Yan J Inflamm Res Review Synovitis, acne, pustulosis, hyperostosis, osteitis (SAPHO) syndrome is a rare autoinflammatory disease characterized by dermatological disorders and osteoarticular inflammatory lesions. This article reviews the application of biologics and other treatments based on the therapeutic target and the size of molecules in SAPHO syndrome. We found that drugs, especially biologics, have different effects on bone, joint, and skin damage. This may relate to the different inflammatory pathways involved in the osteoarticular and cutaneous symptoms in SAPHO patients. In this study, we provide stratified medication recommendations for SAPHO syndrome. Patients with osteoarticular symptoms can consider tumor necrosis factor blockers, JAK inhibitor, interleukin (IL)-1 inhibitor, and IL-17 inhibitor. Patients with cutaneous symptoms should consider IL-17 and JAK inhibitors. Apremilast, Tripterygium wilfordii Hook F, and bisphosphonates are other effective treatments. Dove 2022-04-13 /pmc/articles/PMC9013916/ /pubmed/35444448 http://dx.doi.org/10.2147/JIR.S353539 Text en © 2022 Cheng et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Review Cheng, Wei Li, Fen Tian, Jing Xie, Xi Chen, Jin-Wei Peng, Xiao-Fei Tang, Qi Ge, Yan New Insights in the Treatment of SAPHO Syndrome and Medication Recommendations |
title | New Insights in the Treatment of SAPHO Syndrome and Medication Recommendations |
title_full | New Insights in the Treatment of SAPHO Syndrome and Medication Recommendations |
title_fullStr | New Insights in the Treatment of SAPHO Syndrome and Medication Recommendations |
title_full_unstemmed | New Insights in the Treatment of SAPHO Syndrome and Medication Recommendations |
title_short | New Insights in the Treatment of SAPHO Syndrome and Medication Recommendations |
title_sort | new insights in the treatment of sapho syndrome and medication recommendations |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9013916/ https://www.ncbi.nlm.nih.gov/pubmed/35444448 http://dx.doi.org/10.2147/JIR.S353539 |
work_keys_str_mv | AT chengwei newinsightsinthetreatmentofsaphosyndromeandmedicationrecommendations AT lifen newinsightsinthetreatmentofsaphosyndromeandmedicationrecommendations AT tianjing newinsightsinthetreatmentofsaphosyndromeandmedicationrecommendations AT xiexi newinsightsinthetreatmentofsaphosyndromeandmedicationrecommendations AT chenjinwei newinsightsinthetreatmentofsaphosyndromeandmedicationrecommendations AT pengxiaofei newinsightsinthetreatmentofsaphosyndromeandmedicationrecommendations AT tangqi newinsightsinthetreatmentofsaphosyndromeandmedicationrecommendations AT geyan newinsightsinthetreatmentofsaphosyndromeandmedicationrecommendations |